No hantavirus vaccine is expected to reach approval or licensure by the end of 2026, as all current candidates remain in preclinical or early-phase clinical stages with no Phase 3 trials underway. Recent mRNA efforts by Moderna and partners, along with DNA vaccine research, have shown immunogenicity in animal models as of early 2025, yet these face extended safety testing, manufacturing scale-up, and regulatory review typical for orthohantavirus countermeasures. Outbreaks in 2026 have renewed attention but underscore the absence of licensed options outside limited Asian markets for older HFRS strains. Accelerated emergency pathways remain possible only with unprecedented funding or confirmed surges, though historical timelines and low disease incidence make rapid completion improbable before year-end.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% probabilidad
$129,738 Vol.
$129,738 Vol.
31 dic 2026
6% probabilidad
$129,738 Vol.
$129,738 Vol.
31 dic 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine is expected to reach approval or licensure by the end of 2026, as all current candidates remain in preclinical or early-phase clinical stages with no Phase 3 trials underway. Recent mRNA efforts by Moderna and partners, along with DNA vaccine research, have shown immunogenicity in animal models as of early 2025, yet these face extended safety testing, manufacturing scale-up, and regulatory review typical for orthohantavirus countermeasures. Outbreaks in 2026 have renewed attention but underscore the absence of licensed options outside limited Asian markets for older HFRS strains. Accelerated emergency pathways remain possible only with unprecedented funding or confirmed surges, though historical timelines and low disease incidence make rapid completion improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Mercado abierto: May 4, 2026, 10:39 AM ET
Volumen
$129,738Fecha de finalización
31 dic 2026Mercado abierto
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine is expected to reach approval or licensure by the end of 2026, as all current candidates remain in preclinical or early-phase clinical stages with no Phase 3 trials underway. Recent mRNA efforts by Moderna and partners, along with DNA vaccine research, have shown immunogenicity in animal models as of early 2025, yet these face extended safety testing, manufacturing scale-up, and regulatory review typical for orthohantavirus countermeasures. Outbreaks in 2026 have renewed attention but underscore the absence of licensed options outside limited Asian markets for older HFRS strains. Accelerated emergency pathways remain possible only with unprecedented funding or confirmed surges, though historical timelines and low disease incidence make rapid completion improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volumen
$129,738Fecha de finalización
31 dic 2026Mercado abierto
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No hantavirus vaccine is expected to reach approval or licensure by the end of 2026, as all current candidates remain in preclinical or early-phase clinical stages with no Phase 3 trials underway. Recent mRNA efforts by Moderna and partners, along with DNA vaccine research, have shown immunogenicity in animal models as of early 2025, yet these face extended safety testing, manufacturing scale-up, and regulatory review typical for orthohantavirus countermeasures. Outbreaks in 2026 have renewed attention but underscore the absence of licensed options outside limited Asian markets for older HFRS strains. Accelerated emergency pathways remain possible only with unprecedented funding or confirmed surges, though historical timelines and low disease incidence make rapid completion improbable before year-end.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes